Feasibility of oral insulin shown in insulin-naive patients with type 2 diabetes
Oral insulin 338 (I338) can safely improve glycaemic control in insulin-naive patients with type 2 diabetes with no evidence of a difference compared with insulin glargine. The evidence for its feasibility has been published for the first time in The Lancet Diabetes & Endocrinology online Jan. 21, 2019. I338 is a long-acting, basal insulin analog formulated in a tablet with the absorption-enhancer sodium caprate. Updated AHA/ACC/HRS treatment guideline
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies